Osteoclast precursors, RANKL/RANK, and immunology

Immunological Reviews

Volumn 208, Issue , 2005, Pages 19-29

  Xing, Lianping ^a   Schwarz, Edward M ^a   Boyce, Brendan F ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRITIS; BLOOD LEVEL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNOLOGY; IN VITRO STUDY; MYELOID PROGENITOR CELL; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPLEEN CELL; STEM CELL;

EID: 28544433422     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00336.x     Document Type: Review

References (95)

1. Pettit AR, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-1699.
2. Redlich K, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-1427.
3. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003;42 (Suppl. 2):11-16.
4. Udagawa N, et al. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002;4:281-289.
5. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
6. Yoshida H, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345:442-444.
7. Xing L, et al. Circulating osteoclast precursors: a mechanism and a marker of erosive arthritis. Curr Rheumatol Rev 2005;1:21-28.
8. Dougall WC, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
9. Li P, et al. RANK signaling is not required for TNF alpha-mediated increase in CD11 (hi) osteoclast precursors but is essential for mature osteoclast formation in TNF alpha-mediated inflammatory arthritis. J Bone Miner Res 2004;19:207-213.
10. Seshasayee D, et al. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 2004;279: 30202-30209.
11. + myelopoiesis. Arthritis Res Ther 2004;6:R220-R231.
12. high osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 2004;50:265-276.
13. Ritchlin CT, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-831.
14. Akashi K, et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000;404:193-197.
15. + cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J Bone Miner Res 2001;16:2215-2221.
16. Nutt SL, et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999;401:556-562.
17. Horowitz MC, et al. The origins of osteoclasts. Curr Opin Rheumatol 2004;16:464-468.
18. Matsuo K, et al. Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. Keio J Med 2004;53:78-84.
19. Takayanagi H, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-605.
20. Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
21. Teng YT, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106:R59-R67.
22. Wickenhauser C, et al. Detection and quantification of transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF) release by normal human megakaryocytes. Leukemia 1995;9:310-315.
23. Bord S, et al. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br J Haematol 2004;126: 244-251.
24. Arai F, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999;190:1741-1754.
25. Dai XM, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002;99:111-120.
26. Grall F, et al. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003;48: 1249-1260.
27. Peters CL, et al. The transcription factors hypoxia-inducible factor 1 alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 2004;50:291-296.
28. Redlich K, et al. Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum 2001;44:266-274.
29. Zhang Q, et al. TNF protects osteoclasts from alendronate-induced apoptosis by stimulating Bcl-xL expression through the transcription factor, Ets2. Arthritis Rheum 2005;52:2708-2718.
30. Roodman G. Cell biology of the osteoclast. Exp Hematol 1999;27:1229-1241.
31. Xing L, et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002;17:1200-1210.
32. Kong YY, et al. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 1999;77:188-193.
33. Ikeda F, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004;114:475-484.
34. Matsuo K, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004;279:26475- 26480.
35. Miyamoto T, et al. Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001;98:2544-2554.
36. Miyamoto T, et al. Identification and modulation of common progenitors of osteoclasts and dendritic cells. J Bone Miner Res 2000;15:S219.
37. Rivollier A, et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004;104:4029-4037.
38. Lapidot T, et al. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002;30:973-981.
39. Thomas J, et al. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol 2002;9:183-189.
40. Haringman JJ, et al. Chemokine blockade: a new era in the treatment of rheumatoid arthritis? Arthritis Res Ther 2004;6:93-97.
41. Votta BJ, et al. CKbeta-8 (CCL23), a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. J Cell Physiol 2000;183:196-207.
42. Yu X, et al. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003;18:1404-1418.
43. Aiuti A, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-120.
44. Lapidot T, et al. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m (null) mice. Leukemia 2002;16:1992-2003.
45. Hattori K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001;97: 3354-3360.
46. Moore MA, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann NY Acad Sci 2001;938:36-45.
47. Petit I, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-694.
48. Wright N, et al. Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 2003;101:1978-1984.
49. Choi SJ, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
50. Choi SJ, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108: 1833-1841.
51. Oba Y, et al. MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005;33:272-278.
52. Zhang Y, et al. Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice. J Natl Cancer Inst 2004;96:201-209.
53. Yano S, et al. Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinology 2005;146:2324-2335.
54. Yu X, et al. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 2004;19: 2065-2077.
55. Cappellen D, et al. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. J Biol Chem 2002;277: 21971-21982.
56. Day CJ, et al. Gene array identification of osteoclast genes: differential inhibition of osteoclastogenesis by cyclosporin A and granulocyte macrophage colony stimulating factor. J Cell Biochem 2004;91:303-315.
57. Ishida N, et al. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 2002;277:41147-41156.
58. Quinones MP, et al. The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 2005;83:672-681.
59. Kim MS, et al. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005;280: 16163-16169.
60. Lean JM, et al. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem 2002;87: 386-393.
61. Pascual V, et al. The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 2003;15:548-556.
62. Lean JM, et al. Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. Bone 2000;27:29-40.
63. Delneste Y, et al. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood 2003;101:143-150.
64. Takayanagi H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
65. Yao Z, et al. TNF increases bone marrow osteoclast precursor numbers by stimulating their proliferation and differentiation through up-regulation of c-Fms expression. J Bone Miner Res 2004;19:S171.
66. Wong BR, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-25194.
67. Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
68. Yasuda H, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
69. Boyle WJ, et al. Osteoclast differentiation and activation. Nature 2003;423:337-342.
70. Teitelbaum SL, et al. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-649.
71. Yamashita T, et al. c-Fos over-expression induces osteoclastogenesis independent of RANK signaling. J Bone Miner Res 2002;17:S131.
72. hi osteoclast precursors, but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J Bone Miner Res 2004;19:207-213.
73. Breuil V, et al. The receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) is a new chemotactic factor for human monocytes. FASEB J 2003;17:1751-1753.
74. Mosheimer BA, et al. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 2004;50:2309-2316.
75. Kobayashi K, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191: 275-286.
76. Fuller K, et al. TNF alpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002;143:1108-1118.
77. Lam J, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-1488.
78. Li J, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-1571.
79. Granfar RM, et al. Optimised real-time quantitative PCR assays for RANKL regulated genes. Mol Cell Probes 2005;19:119-126.
80. Redlich K, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46:785-792.
81. Schimpl A, et al. IL-2 and autoimmune disease. Cytokine Growth Factor Rev 2002;13:369-378.
82. Reya T, et al. Abnormal myelocytic cell development in interleukin-2 (IL-2)-deficient mice: evidence for the involvement of IL-2 in myelopoiesis. Blood 1998;91:2935-2947.
83. Ashcroft AJ, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 2003;19:849-861.
84. de Fougerolles AR, et al. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest 2000;105:721-729.
85. Terato K, et al. Collagen-induced arthriritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995;22:137-147.
86. Weyand CM, et al. B cells in rheumatoid synovitis. Arthritis Res Ther 2005;7 (Suppl.):S9-S12.
87. De Togni P, et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994;264:703-707.
88. Rennert PD, et al. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 1998;9:71-79.
89. Fava RA, et al. A role for the lymphotoxin/ LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003;171:115-126.
90. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-4031.
91. Rho J, et al. Osteoimmunology: interactions of the immune and skeletal systems. Mol Cells 2004;17:1-9.
92. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83:170-179.
93. Walsh MC, et al. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003;14:251-263.
94. Josien R, et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162: 2562-2568.
95. Wong BR, et al. TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-2080.